Akebia's Market Potential Undervalued By The Street, Says JMP

JMP reiterated its Market Outperform rating and $16 price target on Akebia Therapeutics Inc AKBA. The company reported a 2Q16 net loss of $35.8 million, or ($0.95) per share vs. JMP's estimate of ($0.59) per share. It also announced initiation of the Phase III INNO2VATE trial of vadadustat in dialysis-dependent patients with anemia related to CKD.

The analysts believe the execution of pipeline milestones represents a more valuable measure of the company's progress than earnings.

"We believe AKBA has a clinical candidate with significant market potential that is currently undervalued by the Street. In our opinion, vadadustat compares favorably to other products under development and has the potential to capture a significant share of the CDK anemia market," wrote JMP.

According to the analysts, the efficacy data for vadadustat look compelling, and they have a high degree of confidence in the management team's ability to advance and commercialize the vadadustat program.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst Ratings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!